Literature DB >> 8860836

Effects of gamma irradiation on the transduction of dividing and nondividing cells in brain and muscle of rats by adeno-associated virus vectors.

I E Alexander1, D W Russell, A M Spence, A D Miller.   

Abstract

Vectors based on adeno-associated virus (AAV) are under investigation for use in gene therapy applications. Critical aspects of AAV vector biology remain undefined, in particular the intracellular events and activities mediating transduction and determining host cell permissiveness for transduction. Using cultured primary human fibroblasts, we previously showed that AAV vectors preferentially, but not exclusively, transduce cells in the S phase of the cell cycle, and that transduction can be markedly enhanced by pretreatment of target cells with physical and chemical agents that perturb DNA metabolism. In this study, we tested whether similar improvements in AAV vector performance might be achievable in vivo. The adult rat brain and overlying scalp muscle were selected for vector inoculation because of the presence of well-defined populations of dividing, quiescent, and post-mitotic cells, and gamma irradiation was chosen as a reproducible means of inducing DNA repair in these cells. We find that gamma irradiation markedly enhances the transduction of dividing cell populations in the pia-arachnoid and choroid epithelium within the central nervous system, and of mature nondividing muscle cells in the scalp, whereas gamma irradiation did not increase the basal transduction level of post-mitotic neurons in the hippocampus. These data confirm that replicative cellular DNA synthesis is not required for transduction by AAV vectors and show that the mitotic state of target cells is not necessarily predictive of responsiveness to transduction-enhancing treatments. Most importantly, these data demonstrate that target cells can be manipulated in vivo to render them more permissive for AAV vector transduction.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8860836     DOI: 10.1089/hum.1996.7.7-841

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  42 in total

1.  Integrating adenovirus-adeno-associated virus hybrid vectors devoid of all viral genes.

Authors:  A Lieber; D S Steinwaerder; C A Carlson; M A Kay
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

2.  Adeno-associated virus type 2-mediated gene transfer: altered endocytic processing enhances transduction efficiency in murine fibroblasts.

Authors:  J Hansen; K Qing; A Srivastava
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

Review 3.  Adeno-associated virus vectors and hematology.

Authors:  D W Russell; M A Kay
Journal:  Blood       Date:  1999-08-01       Impact factor: 22.113

4.  Impaired intracellular trafficking of adeno-associated virus type 2 vectors limits efficient transduction of murine fibroblasts.

Authors:  J Hansen; K Qing; H J Kwon; C Mah; A Srivastava
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

5.  Characterization of promoter function and cell-type-specific expression from viral vectors in the nervous system.

Authors:  R L Smith; D L Traul; J Schaack; G H Clayton; K J Staley; C L Wilcox
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

Review 6.  Gene therapy for liver diseases: recent strategies for treatment of viral hepatitis and liver malignancies.

Authors:  V Schmitz; C Qian; J Ruiz; B Sangro; I Melero; G Mazzolini; I Narvaiza; J Prieto
Journal:  Gut       Date:  2002-01       Impact factor: 23.059

7.  Widespread gene delivery and structure-specific patterns of expression in the brain after intraventricular injections of neonatal mice with an adeno-associated virus vector.

Authors:  M A Passini; J H Wolfe
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

8.  Transduction by adeno-associated virus vectors in the rabbit airway: efficiency, persistence, and readministration.

Authors:  C L Halbert; T A Standaert; M L Aitken; I E Alexander; D W Russell; A D Miller
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

Review 9.  Enhanced prospects for drug delivery and brain targeting by the choroid plexus-CSF route.

Authors:  Conrad E Johanson; John A Duncan; Edward G Stopa; Andrew Baird
Journal:  Pharm Res       Date:  2005-07-22       Impact factor: 4.200

Review 10.  Current status of gene therapy for rheumatoid arthritis.

Authors:  Daniel F Gaddy; Paul D Robbins
Journal:  Curr Rheumatol Rep       Date:  2008-10       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.